
#078: Cladribine (Mavenclad, Leustat, Litak) for highly active MS
Cladribine (Mavenclad, Leustat, Litak) is an induction therapy the supresses the immun system and is used for highly active MS.
Cladribine (Mavenclad, Leustat, Litak) is an induction therapy the supresses the immun system and is used for highly active MS.
Alemtuzumab (Lemtrada, Campath) is a DMT to treat highly active MS and has long-lasting effects and potential severe side effects.
The Expanded Disability Status Scale (EDSS) is a key tool used by neurologists to measure how Multiple Sclerosis (MS) affects
Interferon-beta (Avonex, Betaferon, Extavia, Plegrid,y Rebif) is used as a disease-modifying therapy for mild to moderate RRMS, CIS & SPMS.
Interferon-beta (Avonex, Betaferon, Extavia, Plegrid,y Rebif) is used as a disease-modifying therapy for mild to moderate RRMS, CIS & SPMS.
Interferon-beta (Avonex, Betaferon, Extavia, Plegrid,y Rebif) is used as a disease-modifying therapy for mild to moderate RRMS, CIS & SPMS.
Interferon-beta (Avonex, Betaferon, Extavia, Plegrid,y Rebif) is used as a disease-modifying therapy for mild to moderate RRMS, CIS & SPMS.
Discover how speech therapists can address often overlooked MS-related swallowing and communication disorders for timely intervention.
I show you how to make the best of your life with MS from family to career to hobbies. Thanks to science and research, a lot is possible nowadays.
Then get 11 impulses for a positive course as a gift and receive important information about the disease.
Sign up for the newsletter now and get 11 tips on how you can positively influence your progress.
Wait a moment!
Sign up for the newsletter now and get 11 tips on how you can positively influence your progress.
You need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Facebook. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information